Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study

Détails bibliographiques
Auteurs principaux: Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I
Format: Conference item
Langue:English
Publié: Wiley 2017

Documents similaires